Feedback / Questions
LTZ-301 - LTZ Therap
https://www.businesswire.com/news/home/20250220085305/en/LTZ-Therapeutics-Announces-FDA-Clearance-of-IND-Application-to-Initiate-Trial-of-First-in-Class-Myeloid-Engager-Immunotherapy-LTZ-301
Feb 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next